170784 ⎘
Screening for compounds of potential therapeutic value Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
P-SELECTIN MUTANTS AND MODULATION OF INTEGRIN-MEDIATED SIGNALING
#2Application of GLUN2A and NMDA Receptor Containing GLUN2A as Targets in Screening Drugs for Treating Depression
#3INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS
#4SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF
#5NEW SYNTHETIC DRUGS FOR TREATING ALZHEIMER'S DISEASE
#6APPLICATION FOR PIR-HSA-164586 AND MYH9
#7USE OF A FBXO42 SPECIFIC INHIBITOR IN TREATING NOTCH SIGNALING-DEPENDENT DISEASE
#8ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS OF USE
#9IMPEDING PLATINUM-BASED CHEMOTHERAPEUTIC INDUCED OTOTOXICITY USING A COLONY STIMULATING FACTOR 1 RECEPTOR INHIBITOR
#10SINGLE-MOLECULE PLATFORM FOR DRUG DISCOVERY: METHODS AND APPARATUSES FOR DRUG DISCOVERY, INCLUDING DISCOVERY OF ANTICANCER AND ANTIVIRAL AGENTS
#11METHODS OF INHIBITING PARAMYXOVIRIDAE FUSION TO A TARGET CELL
#12System and Method for Drug-Related Data Collection and Analysis
#13METHODS OF OPTIMIZING KINASE INHIBITORS
#14ANTI-FCRN ANTIBODIES
#15FLUORESCENTLY-LABELED F-ACTIN PROTEIN BIOSENSORS AND METHODS OF HIGH-THROUGHPUT DRUG DISCOVERY
#16CHLORAMPHENICOL RESISTANT SPLIT PROTEIN AND USES THEREOF
#17CHEMIGENETIC TOOLS AND METHODS OF CONTROLLING AND ASSESSING PROTEIN PHASE SEPARATION
#18COMPOSITIONS, ASSAYS, AND METHODS FOR DIRECT MODULATION OF FATTY ACID METABOLISM
#19METHOD FOR CONSTRUCTING HOTSPOT-DERIVED PEPTIDE-NUCLEIC ACID HYBRID MOLECULES ON BASIS OF IN VITRO SELECTION
#20SINGLE DOMAIN ANTIBODIES FOR THE DETECTION OF PLASMIN-CLEAVED VWF
#21MOLECULAR INDEXING OF PROTEINS BY SELF ASSEMBLY (MIPSA) FOR EFFICIENT PROTEOMIC INVESTIGATIONS
#22Food Protein-Derived Peptides as Bitter Taste Blockers
#23BEAD-BASED ASSAY TO SCREEN FOR INHIBITOR PROTEIN-GLYCAN INTERACTIONS IN NEURODEGENERATION
#24Binding Domains Directed Against GPCR:G Protein Complexes and Uses Derived Thereof
#25Method of modulating autoimmunity by disrupting cis-ligand binding of siglec type antigens
#26HIGH-THROUGHPUT ENGINEERING OF MOLECULAR GLUES
#27INTERNALLY FIXED LIPID VESICLE
#28METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
#29BACTERIAL SYSTEMS FOR ANALYZING UBIQUITYLATED POLYPEPTIDES
#30METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE
#31MECHANISM OF ACTION
#32SENOLYTIC DRUG SCREENING METHOD AND SENOLYTIC DRUG
#33METHOD FOR OPTIMIZING DRUG SELECTION
#34CHLORAMPHENICOL RESISTANT SPLIT PROTEIN AND USES THEREOF
#35RECOMBINANT POLYPEPTIDE FOR DISRUPTING INTERACTION OF EAG2 AND KVß2 AND THERAPEUTIC APPLICATIONS THEREOF IN CANCER TREATMENT
#36EXTRACELLULAR VESICLE DRUG ANALYSIS FOR REAL-TIME MONITORING OF TARGETED THERAPY
#37Covalent Molecular Glue Stabilizers and Platform
#38SINGLE-MOLECULE PLATFORM FOR DRUG DISCOVERY: METHODS AND APPARATUSES FOR DRUG DISCOVERY, INCLUDING DISCOVERY OF ANTICANCER AND ANTIVIRAL AGENTS
#39IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
#40Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases
#41PEPTIDE FOR TREATING AGE-RELATED MACULAR DEGENERATION
#42METHOD FOR DETECTING EXPRESSION OR CLUSTERING OF CELL SURFACE MOIETIES
#43CELL DEATH BIOMARKER
#44SYSTEM AND METHOD FOR HOMOGENOUS GPCR PHOSPHORYLATION AND IDENTIFICATION OF BETA-2 ADRENERGIC RECEPTOR POSITIVE ALLOSTERIC MODULATORS
#45MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
#46Desmoglein 2 (DSG2) Binding Proteins and Uses Therefor
#47DEVICE AND METHOD FOR CELL-BASED DRUG SCREENING
#48BIOSYSTEMS TO DETECT CHEMICAL CONTAMINANTS
#49PVRIG POLYPEPTIDES AND METHODS OF TREATMENT
#50METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HERPESVIRUSES
#51Compositions and methods involving engineered P27
#52PEPTIDE MIMOTOPES OF CLAUDIN 18.2 AND USES THEREOF
#53Cell-Free Method For The Quantitative Measurement Of Virus Neutralizing Antibodies
#54METHOD FOR SCREENING COLORECTAL CANCER METASTASIS INHIBITOR
#55YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS
#56METHOD FOR DETERMINING WHETHER OR NOT VIRUS-NEUTRALIZING ANTIBODIES ARE PRESENT AND IN VITRO METHOD FOR SCREENING COMPOUNDS FOR THEIR ABILITY TO NEUTRALIZE A VIRUS
#57COMPOSITIONS AND METHODS FOR TREATMENT
#58COMPOSITIONS, ASSAYS, AND METHODS FOR DIRECT MODULATION OF FATTY ACID METABOLISM
#59IN VITRO HBV CORE PROTEIN ASSAY
#60ANALYSIS, SCREENING, AND SELECTION FOR SOLUBLE PROTEIN FUNCTION IN SECRETED PROTEIN CELL LIBRARIES
#61MODULATOR ASSAY
#62Compounds for Treating Tauopathies and Restless Leg Syndrome and Methods of Using and Screening for Same
#63UNBLENDING OF TRANSCRIPTIONAL CONDENSATES IN HUMAN REPEAT EXPANSION DISEASE
#64RING NUCLEASE
#65Method for Measuring Modulation in the Activity of a G Protein-Coupled Receptor
#66STABILIZATION OF MHC COMPLEXES
#67Anti-FcRn Antibodies
#68TOOLS AND METHODS FOR EXPRESSION OF MEMBRANE PROTEINS
#69NECROPTOSIS MODULATORS, SCREENING METHODS AND PHARMACEUTICAL COMPOSITIONS
#70METHODS FOR IDENTIFYING ANTI CLOSTRIDIAL NEUROTOXIN COMPOUNDS
#71ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS OF USE
#72METHOD AND PLATFORM FOR ENHANCING DETECTION ACTIVITY OF INTERACTION BETWEEN SPIKE PROTEIN RECEPTOR BINDING DOMAIN OF CORONAVIRUS FROM SPECIMEN AND HUMAN ANGIOTENSIN-CONVERTING ENZYME II
#73Modulators of ATP-binding cassette transporters
#74HIGH-THROUGHPUT ENZYME ASSAY FOR SCREENING ACTIVITY OF ACYLTRANSFERASES
#75METHODS OF CHARACTERIZING AND UTILIZING AGENT-CONDENSATE INTERACTIONS
#76COMPOSITIONS AND METHODS FOR MEASURING AND INHIBITING CALPAIN-5 ACTIVITY
#77METHOD FOR IDENTIFYING UBIQUITIN AND UBIQUITIN-LIKE ENZYME ACTIVITIES
#78METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH2 MEDIATED DISEASES
#79PTPRS AND PROTEOGLYCANS IN AUTOIMMUNE DISEASE
#80BLOOD BRAIN BARRIER-ON-A-CHIP
#81ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS
#82PHARMACEUTICALS AND METHODS FOR TREATING HYPOXIA AND SCREENING METHODS THEREFOR
#83ANTAGONISTS OF CAMKII-DELTA 9 AND USES THEREOF
#84Novel Selective ACKR3 Modulators and Uses Thereof
#85HIGH THROUGHPUT DRUG SCREENING METHODS
#86ANTIGEN-BINDING MOLECULE CONTAINING ANTIGEN-BINDING DOMAIN OF WHICH BINDING ACTIVITY TO ANTIGEN IS CHANGED DEPENDING ON MTA, AND LIBRARY FOR OBTAINING SAID ANTIGEN-BINDING DOMAIN
#87METHODS AND KITS FOR THE DIAGNOSIS OF INFLUENZA
#88Desmoglein 2 (DSG2) binding proteins and uses therefor
#89METHOD FOR MEASURING THE MODULATION OF THE ACTIVATION OF A G PROTEIN-COUPLED RECEPTOR WITH GTP ANALOGUES
#90E3 UBIQUITIN LIGASE (UBE3A) PROTEIN TARGETS
#91METHOD FOR IDENTIFYING MODULATORS OF G3BP ACTIVITY
#92VITRO ASSAY FOR DRUG DISCOVERY OF VALVULAR HEART DISEASE
#93KLOTHO BETA
#94IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
#95Methods of use of anti-TNFα antibodies
#96Energy drinks and other nutritional aids derived from agave-based spirits
#97METHODS FOR DIAGNOSING OR TREATING POST-TRAUMATIC STRESS DISORDER, AND COMPOSITIONS THEREFOR
#98COMPOSITIONS AND METHODS FOR DETERMINING CORONAVIRUS NEUTRALIZATION TITERS
#99Quantum Dot Conjugated Virus Spike Protein for Cell-Based Bio-Sensing Systems and Drug Screening
#100PARTICLE BASED SMALL MOLECULE-PROTEIN COMPLEX TRAP
#101ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS OF USE
#102METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
#103Compounds inhibiting Nef-calnexin interaction
#104METHOD FOR PREVENTING OR TREATING HEART FAILURE BY ADMINISTERING A MEDICAMENT CONTAINING AN ANTAGONIST OF CORTICOTROPIN RELEASING HORMONE RECEPTOR 2 (CRHR2)
#105Modulators of ROR1-ROR2 binding
#106Antibodies against signal-regulatory protein alpha and methods of use
#107Fusion proteins comprising extracellular domain of human CD22
#108INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS
#109NOVEL METHOD FOR TRANSDUCING PROTEIN-PROTEIN INTERACTIONS
#110METHODS FOR PRECISION THERAPEUTIC TARGETING OF HUMAN CANCER CELL MOTILITY AND KITS THEREOF
#111Composition and Methods for Measuring Antibody Dynamics
#112KLOTHO BETA
#113BACTERIAL SYSTEMS FOR ANALYZING UBIQUITYLATED POLYPEPTIDES
#114Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus Receptor
#115Engineered renal tissues, arrays thereof, and methods of making the same
#116HIF-1 and HIF-2 inhibitors
#117Peptides and nanoparticle formulations thereof
#118COMPOSITIONS AND METHODS FOR REDUCTION OF LIPOPROTEIN A FORMATION AND TREATMENT OF AORTIC VALVE SCLEROSIS AND AORTIC STENOSIS
#119Purification and identification of a protein complex containing b-cell lymphoma protein (BCL10)
#120MECHANISM OF ACTION
#121ANTIBODY
#122Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
#123Methods of screening for sortilin binding antagonists
#124METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS
#125PROPHYLACTIC OR THERAPEUTIC AGENT FOR TUMORS, PD-L1 INHIBITOR, SCREENING METHOD FOR PROPHYLACTIC OR THERAPEUTIC AGENT FOR TUMORS, AND SCREENING METHOD FOR PD-L1 INHIBITOR
#126Method of identifying potential inhibitors of APO TNFα trimers
#127PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF
#128PHENOXY THIOPHENE SULFONAMIDES AND OTHER COMPOUNDS FOR USE AS INHIBITORS OF BACTERIAL GLUCURONIDASE
#129Compositions and methods for modulating left-right differentiation factor (LEFTY) and bone morphogenic factor (BMP)
#130DISCOVERY OF NOVEL MOLECULES AND REPURPOSED DRUGS FOR RAS FAMILY GTPases
#131SCREENING ASSAYS AND KITS FOR CHARACTERIZING AN ABILITY OF A CANDIDATE COMPOUND TO MODULATE A BINDING AFFINITY BETWEEN AN FBW7 PROTEIN AND AN FBW7 SUBSTRATE
#132Method of treating inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) or gluten hypersensitivity by administering an elastase 2A (ELA2A) inhibitor
#133SCREENING METHOD FOR THE IDENTIFICATION OF CANCER THERAPEUTICS
#134METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTS
#135Ligase Screening Assay
#136TRAF 6 inhibitors
#137Compositions and methods involving engineered p27
#138Compositions, assays, and methods for direct modulation of fatty acid metabolism
#139Method for identifying modulators of G3BP activity
#140Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptors
#141Method for inhibiting the expression of inflammation promoting factors
#142Chloramphenicol resistant split protein and uses thereof
#143PVRIG polypeptides and methods of treatment
#144Ligand binding assay for detecting gibberellins
#145Glycosylation site-specific antibodies and anti-cancer compounds
#146PEPTIDE FOR TREATING AGE-RELATED MACULAR DEGENERATION
#147HISTAMINE-RELEASING FACTOR (HRF), HRF-RECEPTOR AND METHODS OF MODULATING INFLAMMATION
#148ASPRV1 AS A NEUTROPHIL-SPECIFIC MARKER AND THERAPEUTIC TARGET FOR INFLAMMATORY DISEASES
#149Compounds inhibiting Nef-calnexin interaction
#150CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION
#151Chimeric proteins and their use in identifying anti-deubiquitinase compounds
#152Screening method for materials that suppress characteristic body odor of elderly people
#153Single-molecule platform for drug discovery: methods and apparatuses for drug discovery, including discovery of anticancer and antiviral agents
#154Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
#155Desmoglein 2 (DSG2) binding proteins and uses therefor
#156Methods of identifying a moldulator of otopetrin-mediated proton translocation activity
#157AGENT FOR CONTROLLING CELLS CONSTITUTING CANCER MICROENVIRONMENT OR INFLAMMATORY MICROENVIRONMENT
#158KDAC VARIANTS AND USES THEREOF
#159Binding domains directed against GPCR:G protein complexes and uses derived thereof
#160Tau aggregation peptide inhibitors
#161PHARMACEUTICALS AND METHODS FOR TREATING HYPOXIA AND SCREENING METHODS THEREFOR
#162Methods for establishing colorectal cancer p73 reporter gene cell line
#163METHODS FOR MODULATING THE INTERACTION BETWEEN EWS-FLI1 AND BAF COMPLEXES
#164COMBINED ANTICANCER AGENT SENSITIVITY DETERMINATION MARKER
#165SCREENING SYSTEM AND METHODS FOR IDENTIFYING ENZYME SUBSTRATES AND MODULATORS OF ENZYME ACTIVITY
#166ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF CANCERS
#167MICROTUBULE-TARGETING DRUGS AS IMMUNE CHECKPOINT INHIBITORS AND METHODS OF SCREENING NOVEL IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCERS AND INFECTIOUS DISEASES
#168Small molecules blocking histone reader domains
#169COMPOSITIONS AND METHOD FOR IDENTIFYING ENZYME AND TRANSPORT PROTEIN INHIBITORS
#170Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
#171FKBP52-TAU INTERACTION AS A NOVEL THERAPEUTICAL TARGET FOR TREATING THE NEUROLOGICAL DISORDERS INVOLVING TAU DYSFUNCTION
#172Compounds and methods used in assessing mono-PARP activity
#173Compositions and methods for programmable sensing and control through combinatorial molecular interactions
#174Modulators of ATP-binding cassette transporters
#175Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
#176Agents that modulate immune cell activation and methods of use thereof
#177KITS, METHODS AND THEIR USES FOR DETECTING CELL-CELL INTERACTIONS IN A SAMPLE KITS
#178Specific GNAI:GIV interaction screening assays, methods and compositions
#179Soluble CD33 for treating myelodysplastic syndromes (MDS)
#180METHODS OF ASSESSING PROTEIN INTERACTIONS BETWEEN CELLS
#181PEPTIDE MIMOTOPES OF CLAUDIN 18.2 AND USES THEREOF
#182Compositions and methods for treating multiple myeloma
#183Assays using arrestin recruitment and unmodified receptors
#184DIAGNOSTIC AND SCREENING METHODS FOR ATOPIC DERMATITIS
#185Preparation and application of immortalized alpha-1,3-galactosyltransferase gene knockout pig hepatocyte cell line
#186Γ-secretase stabilizing compound screening assay
#187Methods and kits for the diagnosis of influenza
#188RNA-YY1 Interactions
#189Autophagy enhancer and use thereof
#190Material for screening for compound acting on ION channel and use thereof
#191Membrane span-kinase fusion protein and the uses thereof
#192CRY1-Clock-BMAL1 Complex-Disrupting Agents and Methods of Identifying and Using Same
#193Cancer Treatment and Immune System Regulation Through FAT10 Pathway Inhibition
#194METHOD FOR DETERMINING ALZHEIMER'S DISEASE RISK
#195Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
#196METHODS AND COMPOSITIONS FOR MODULATING CANCER STEM CELLS
#197Cell death biomarker
#198Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same
#199Reporter construct and biosensor for interferon second messenger 2-5A
#200Anti-FcRn antibodies
#201Expression Inhibitor of Inflammation Promoting Factor, Screening Method for Active Ingredient Thereof, Expression Cassette Useful for Said Method, Diagnostic Agent and Diagnosis Method
#202System and method for homogenous GPCR phosphorylation and identification of beta-2 adrenergic receptor positive allosteric modulators
#203Methods of identifying modulators of SAMTOR-GATOR1 interaction and use of same to modulate mTORC1
#204Juvenile atopic dermatitis models
#205Energy drinks and other nutritional aids derived from agave-based spirits
#206Therapeutic agents for neurological and psychiatric disorders
#207Targeting dimerization of BAX to modulate BAX activity
#208Bacterial systems for analyzing ubiquitylated polypeptides
#209Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
#210Combination therapies and methods of use thereof
#211Method of screening a candidate compound for activity as an elastase 2A (ELA2A) inhibitor
#212METHOD FOR PREDICTING EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN CANCER PATIENTS
#213Internally fixed lipid vesicle
#214Targeting fibroblast invasion for pulmonary fibrosis
#215Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2)
#216Screening method of drug candidates for treating disease using interaction between calcium and phosphatidylinositol phosphate
#217METHODS OF IDENTIFYING CFTR MODULATORS
#218PEPTIDES OF BROMODOMAIN TESTIS-SPECIFIC PROTEIN (BRDT)
#219METHODS OF MODULATING BCKDH
#220DEVICE AND METHOD FOR CELL-BASED DRUG SCREENING
#221TFPI inhibitors and methods of use
#222METHODS OF DOWNREGULATING TRANSLOCATED ONCOGENE EXPRESSION USING BROMODOMAIN INHIBITORS
#223METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TH2 MEDIATED DISEASES
#224METHOD OF DETERMINING AUTOPHAGOSOME FLUX AND USES THEREOF
#225Method for determining breast cancer treatment
#226Polypeptides and polypeptide constructs comprising single domain antibodies directed against von willebrand factor
#227METHODS FOR IDENTIFYING AND TREATING HEMOGLOBINOPATHIES
#228Calcium sensing receptors, ligands, compositions, and methods of use
#229Chimeric proteins and their use in identifying anti-deubiquitinase compounds
#230METHODS AND MATERIALS FOR MODULATING DEUBIQUITINASES AND UBIQUITINATED POLYPEPTIDES
#231Screening method of anticancer agent focused on function of HP1 and evaluation system
#232INHIBITION OF IL-17 PRODUCTION
#233Desmoglein 2 (DSG2) binding proteins and uses therefor
#234Therapies for cardiomyopathy
#235Polypeptides and uses thereof for reducing CD95-mediated cell motility
#236Methods of assessing protein interactions between cells
#237METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
#238Method for determining kinetic profiles in drug discovery
#239COMPOSITIONS AND METHODS FOR IDENTIFYING ENZYME MODULATORS OR INHIBITORS
#240Engineered renal tissues, arrays thereof, and methods of making the same
#241BIOLOGICAL MATERIALS AND USES THEREOF
#242HIF-1 and HIF-2 inhibitors
#243METHOD FOR USING BIOLOGICAL MATERIAL FOR DETERMINATION OF DIFFERENCES IN BINDING TO A MOLECULE OF INTEREST
#244Compounds inhibiting Nef-calnexin interaction
#245Method for screening anticancer agent inhibiting binding of AIMP2-DX2 and HSP70
#246Methods of screening and treatment with USP4 inhibitors
#247MIC-1 receptor and uses thereof
#248Methods of identifying modulators of CASTOR1-GATOR2 interaction and use of same to modulate mTORC1
#249Antiviral drugs
#250Methods and compositions for treating neurodegenerative and neuroinflammatory conditions
#251Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
#252Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway
#253Inflammatory Disease Treatment Composition Including Anti-Myosin Regulatory Light-Chain Polypeptide Antibody
#254COMPOSITIONS TARGETING PKC-THETA AND USES AND METHODS OF TREATING PKC-THETA PATHOLOGIES, ADVERSE IMMUNE RESPONSES AND DISEASES
#255Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
#256Methods of treating or preventing pruritis by blocking natriuretic polypeptide b
#257Ovary Tumor Markers And Methods Of Use Thereof
#258Epidithiodioxopiperazine compound or its derivatives, and the use thereof
#259Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family
#260Screening for anti-cancer compounds using netrin-1 activity
#261Peptides for blocking IL1RAP protein-protein interaction and uses thereof for treatment of disease
#262Medical Use
#263Complement split product C4d for the treatment of inflammatory conditions
#264Methods and reagents for analyzing protein-protein interfaces
#265B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
#266Methods and reagents for analyzing protein-protein interfaces
#267Methods for increasing levels of interferon activity with an interferon lambda 3 polypeptide
#268Suppression of SPLA2-integrin binding for treating an inflammatory condition or suppressing cell proliferation
#269Tools and methods for expression of membrane proteins
#270Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers
#271Screening Methods
#272Method of treating pain with an antibody against netrin-4, UNC5B or neogenin
#273Miniature protein scaffolds and methods for use thereof
#274PCSK9 INHIBITORY POLYPOLYPEPTIDES AND METHODS OF USE
#275Methods of identifying signaling modulators of the trimeric TNFa
#276Single-Molecule Platform For Drug Discovery: Methods And Apparatuses For Drug Discovery, Including Discovery Of Anticancer And Antiviral Agents
#277ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF CANCERS
#278Chimeric fibroblast growth factor 21 proteins and methods of use
#279SMALL MOLECULE INHIBITORS OF GP120-MEDIATED HIV INFECTION AND METHODS OF USE
#280TNF receptor signaling modulator assay
#281Antibodies binding to trimeric TNF alpha epitopes
#282Dynamic Light Scattering Nanoplatform For High-Throughput Drug Screening
#283Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding them
#284Protein degradation inducing tag and usage thereof
#285Modulators of ATP-binding cassette transporters
#286FKBP52-TAU INTERACTION AS A NOVEL THERAPEUTICAL TARGET FOR TREATING THE NEUROLOGICAL DISORDERS INVOLVING TAU DYSFUNCTION
#287Antifugetactic agents for the treatment of cancers
#288SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS
#289Enzymatic modification of nucleic acids
#290Inhibitors of mitochondrial fission and methods of use thereof
#291Methods of identifying SENP1 inhibitors
#292Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
#293Modulators of ROR1-ROR2 binding
#294Antibodies against signal-regulatory protein alpha and methods of use
#295METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR
#296Diagnostic and screening methods for atopic dermatitis
#297Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
#298ANTI-FUGETACTIC AGENTS FOR THE TREATMENT OF CANCERS
#299ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF CANCERS
#300ANTIFUGETACTIC AGENTS FOR THE TREATMENT OF CANCERS